Simultaneous presence of lung adenocarcinoma and malignant pleural mesothelioma: A case report

被引：1
作者：
Yamazoe, Masatoshi [1 ]
Tomioka, Hiromi [1 ]
Kamada, Takahiro [2 ]
Kaneko, Masahiro [1 ]
Katsuyama, Eiji [3 ]
机构：
[1] Kobe City Med Ctr West Hosp, Dept Resp Med, Kobe, Hyogo, Japan
[2] Natl Canc Ctr, Div Canc Immunol, Res Inst EPOC, Chiba, Japan
[3] Kobe City Med Ctr West Hosp, Dept Pathol, Kobe, Hyogo, Japan
来源：
RESPIRATORY MEDICINE CASE REPORTS | 2019年 / 26卷
关键词：
Malignant pleural mesothelioma; Lung cancer; Multiple primary cancer; Simultaneous; Autopsy; CELL CARCINOMA; PHASE-III; CONCURRENT MESOTHELIOMA; PROGNOSTIC-FACTORS; DIAGNOSIS; EXPRESSION; GUIDELINES; CISPLATIN; SURVIVAL; PATIENT;
D O I：
10.1016/j.rmcr.2018.11.011
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
The co-presence of malignant pleural mesothelioma (MPM) and lung cancer is rare. We report a 70-year-old male with exposure to asbestos. Chest computed tomography revealed a right mediastinal mass combined with an enlarged ipsilateral lymph node and left pleural effusion. Transbronchial lung biopsy revealed lung adenocarcinoma. Thoracoscopic examination revealed multiple left pleural nodules, leading to the diagnosis of MPM. Despite aggressive anticancer drug therapy, he expired due to disease progression 2.5 years after diagnosis. Autopsy confirmed an epithelioid MPM in the left pleura. MPM comorbidity in patients diagnosed with lung cancer should be considered, especially in those exposed to asbestos.
引用
收藏
页码：45 / 49
页数：5
相关论文
共 35 条
  • [11] Haber SE., 2010, Resp Med CME, V3, P160, DOI [10.1016/j.rmedc.2009.09.006, DOI 10.1016/J.RMEDC.2009.09.006]
  • [12] Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2012 Update of the Consensus Statement from the International Mesothelioma Interest Group
    Husain, Aliya N.
    Colby, Thomas
    Ordonez, Nelson
    Krausz, Thomas
    Attanoos, Richard
    Beasley, Mary Beth
    Borczuk, Alain C.
    Butnor, Kelly
    Cagle, Philip T.
    Chirieac, Lucian R.
    Churg, Andrew
    Dacic, Sanja
    Fraire, Armando
    Galateau-Salle, Francoise
    Gibbs, Allen
    Gown, Allen
    Hammar, Samuel
    Litzky, Leslie
    Marchevsky, Alberto M.
    Nicholson, Andrew G.
    Roggli, Victor
    Travis, William D.
    Wick, Mark
    [J]. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2013, 137 (05) : 647 - 667
  • [13] Imenpour H, 2013, PATHOLOGICA, V105, P353
  • [14] Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma
    Jassem, Jacek
    Ramlau, Rodryg
    Santoro, Armando
    Schuette, Wolfgang
    Chemaissani, Assad
    Hong, Shengyan
    Blatter, Johannes
    Adachi, Susumu
    Hanauske, Axel
    Manegold, Christian
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (10) : 1698 - 1704
  • [15] Kishimoto Takumi, 2003, Nihon Kokyuki Gakkai Zasshi, V41, P304
  • [16] Collision tumour of the pleura composed of small cell carcinoma and malignant mesothelioma
    Lee, AHS
    Soomro, IN
    [J]. HISTOPATHOLOGY, 2004, 45 (03) : 305 - 306
  • [17] Minute localized malignant pleural mesothelioma coexisting with multiple adenocarcinomas
    Maeda R.
    Isowa N.
    Onuma H.
    Miura H.
    Tokuyasu H.
    Kawasaki Y.
    [J]. General Thoracic and Cardiovascular Surgery, 2010, 58 (2) : 91 - 94
  • [18] Double cancer comprising malignant pleural mesothelioma and squamous cell carcinoma of the lung treated with radiotherapy: A case report
    Negi, Yoshiki
    Kuribayashi, Kozo
    Doi, Hiroshi
    Funaguchi, Norihiko
    Koda, Yuichi
    Fujimoto, Eriko
    Mikami, Koji
    Minami, Toshiyuki
    Yokoi, Takashi
    Kijima, Takashi
    [J]. MOLECULAR AND CLINICAL ONCOLOGY, 2018, 9 (02) : 181 - 186
  • [19] PD-L1 expression associated with worse survival outcome in malignant pleural mesothelioma
    Nguyen, Bella Hai
    Montgomery, Renn
    Fadia, Mitali
    Wang, Jiali
    Ali, Sayed
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 (01) : 69 - 73
  • [20] Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer
    Ohigashi, Y
    Sho, M
    Yamada, Y
    Tsurui, Y
    Hamada, K
    Ikeda, N
    Mizuno, T
    Yoriki, R
    Kashizuka, H
    Yane, K
    Tsushima, F
    Otsuki, N
    Yagita, H
    Azuma, M
    Nakajima, Y
    [J]. CLINICAL CANCER RESEARCH, 2005, 11 (08) : 2947 - 2953
1234